Research library

A

grade

Most tirzepatide-treated participants with prediabetes maintained limited weight regain after reaching their lowest weight, but this may not be clinically significant.

Mean weight regain from nadir to Week 176 was 3.8 kg for 5 mg, 4.4 kg for 10 mg, and 3.7 kg for 15 mg.

summary

B

grade

Tirzepatide may improve fasting glucose control more effectively than semaglutide due to greater suppression of hepatic glucose production, but detailed numeric outcomes are not provided.

Not reported in abstract.

summary

D

grade

Tirzepatide may be associated with reduced cardiovascular events and mortality in patients with type 2 diabetes and established cardiovascular disease, but further investigation is needed to confirm these findings.

HR 0.72; 95% CI 0.55, 0.94 for MACE-3 comparing tirzepatide versus placebo.

summary

B

grade

Tirzepatide may be associated with lower odds of mechanical complications and infections compared to semaglutide in patients undergoing major joint surgeries, but the clinical relevance of these findings should be considered cautiously.

At 2 years, tirzepatide exposure was associated with lower odds of mechanical complications (OR 0.64, 95% CI 0.42 to 0.96).

summary

C

grade

Tirzepatide may preserve hematopoietic stem cell function and reduce inflammatory monocytes compared to caloric restriction during weight loss, but the implications for human treatment require further investigation.

Not reported in abstract.

summary

D

grade

Tirzepatide can lead to significant weight loss, but it may also result in reduced dietary intake and nutritional deficiencies that require careful management.

Mean body-weight reduction of 20.9% with tirzepatide in phase 3 trials.

summary

B

grade

Weight loss was observed in patients starting tirzepatide at doses below 2.5 mg weekly, but the findings are preliminary and should be interpreted with caution.

Mean body-weight loss was 6.10% (95% CI 4.60-7.60; n=8) in the 60-89-day window at a median 65.5 days.

summary

C

grade

A novel NIR-triggered scaffold shows promise for controlled drug release in bone repair, but human trials are needed to confirm clinical applicability.

Bacterial inhibition rate of 99%.

summary

D

grade

Not reported in abstract.

summary

A

grade

This trial demonstrates a successful approach to enrolling participants for Long COVID research using a remote, decentralized model, but efficacy results are not yet available.

1,058 participants enrolled in 73 days.

summary

B

grade

Tirzepatide may lead to significant reductions in body weight and insulin requirements in patients with partial lipodystrophy, but further prospective studies are needed to confirm these results.

Body weight reduced from 91.0 kg (IQR 75.0 - 106.0) to 82.8 kg (IQR 69.0 - 93.4; p<0.0001).

summary

A

grade

All three types of zirconia FDPs showed high survival rates over five years, but monolithic designs had no technical complications, unlike the veneered options.

Survival at 5 years was 94.7% for MONO-FDPs, 100% for FV-FDPs, and 100% for PV-FDPs.

summary

B

grade

Not reported in abstract.

summary

B

grade

Tirzepatide treatment for 12 weeks resulted in an average weight loss of 8.75 kg, primarily from fat mass, with a relative preservation of lean mass.

Body weight decreased by 8.75 kg (-8.18%, P < 0.001)

summary

D

grade

Not reported in abstract.

summary

B

grade

This study highlights the need for enhanced surveillance of plasmid transmission in Klebsiella pneumoniae to mitigate public health risks.

0.37% ST23-K1 strains detected among 1069 CRKP bloodstream isolates.

summary

D

grade

There is a reported odds ratio of 1.36 for serious acute biliary events with glucagon-like peptide-1 therapies compared to sodium-glucose cotransporter-2 inhibitors, but this does not establish causality or incidence.

1.36 reporting odds ratio (95% CI 1.06-1.75; P = 0.013)

summary

B

grade

A significant majority of people with obesity using tirzepatide report high satisfaction and a willingness to recommend the treatment. However, the findings are based on self-reported data and may not reflect broader experiences.

90% (n=45/48) of PwO reported likelihood to recommend tirzepatide.

summary

B

grade

GLP-1 receptor agonist therapy led to significant weight loss and reduced energy intake, but did not improve diet quality or food cravings in a small cohort of adults with obesity.

Weight loss of approximately 5.5 kg, n=28, P<0.001.

summary

B

grade

Tirzepatide appears to be associated with lower annual pharmacy costs per patient achieving specific diabetes treatment targets compared to semaglutide, particularly at stricter endpoints.

Cost per patient achieving HbA1c ≤6.5%, weight loss ≥15%, and no hypoglycemia was GBP 5,650 lower with tirzepatide 5 mg compared to semaglutide 1 mg.

summary

D

grade

The economic model suggests that tirzepatide may be a cost-effective treatment for obesity, with ICERs between £8,327 and £10,157 per QALY gained compared to diet and exercise.

ICERs: £8,327-£10,157 per QALY gained.

summary

C

grade

Tirzepatide may reduce testicular inflammation and improve sperm motility in diabetic mice, but its relevance to human fertility is unclear.

1.00 nmol/kg/day tirzepatide reduced HbA1c levels, p<0.001.

summary

B

grade

In older adults, significant weight loss associated with tirzepatide may increase the risk of frailty and mortality, highlighting the need for careful monitoring and clinical decision-making.

Mortality risk ratio was 25 (95% CI 18-35) for patients developing frailty phenotypes after tirzepatide initiation.

summary

B

grade

Branded and compounded tirzepatide show statistically equivalent effectiveness in weight loss, making the choice largely a cost decision based on the patient's insurance coverage.

Mean weight loss 11.4% for both compounded and branded formulations after matching, difference +0.08 pp, 95% CI −0.70 to +0.80.

summary

D

grade

This study highlights that 75 clinics are offering compounded GLP-1 RAs, but some facilities lack proper licensing, which raises safety concerns.

75 weight-loss clinics and medical spas identified offering compounded GLP-1 RAs.

summary